Physician profile
Alan J Anthony
NPI 1114003415
$1,188.16
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $94.54 · 2021: $136 · 2022: $160 · 2023: $335 · 2024: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $422.53 | 2019-2024 | Tremfya, Remicade, Simponi |
| Abbvie INC. | $202.76 | 2019-2024 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $158.16 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $89.92 | 2019-2024 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $71.71 | 2019 | |
| Biofrontera INC. | $39.03 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Prugen, INC. Pharmaceuticals | $35.00 | 2020 | |
| Ucb, INC. | $31.27 | 2021-2024 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.12 | 2021-2022 | |
| Organogenesis INC. | $22.30 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.11 | 2023 | Spevigo |
| Teleflex LLC | $16.25 | 2024 | Urolift |
| Pfizer INC. | $14.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.27 | 2024 | Sotyktu |
| Boston Scientific Corporation | $13.78 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.